Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.

NCT02352181 | Completed

• 1 other identifier: 2014-870
• Study Type: interventional
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

In current practice, management of coagulation during liver transplantation is performed either through standard coagulation status or with ROTEM® depending on practitioner choice and availability of materials. In this context, the ROTEM® is used since over 2 years by anesthesiologists in the digestive surgery department of the Croix Rousse hospital in Lyon, France. Indeed liver transplantation surgery is at high risk of bleeding due to coagulopathy developed by patients who are eligible, due to coagulation factor synthesis deficiencies in the cirrhotic liver. On the other hand the standard coagulation profile is a poor reflection of coagulopathy in such patients because the imbalance between pro- and anti-coagulant factors are not taken into account by PT and aPTT measures. Management of intraoperative hemorrhage may be facilitated by the ROTEM® which is performed from whole blood and which allows the detection of abnormalities in the balance between pro- and anti-coagulant factors. This technique was already evaluated in liver, cardiac, and obstetric surgery but also in traumatology. Randomized trials in liver transplantation surgery have shown changes in transfusion practices but did not focus on the consequences of such changes.

Conditions

Liver Transplantation

Keywords

Cirrhosis, transplantation, transfusion, Rotem®

Outcome Measures

Primary Outcomes (1)

• Amount of blood product (in milliliter) transfused during liver transplantation.

  Assessing the impact of intraoperative management of coagulation by ROTEM® compared to the conventional management (standard coagulation profile) on the amount of blood product units (in milliliter) transfused during liver transplantation.

  During time of liver transplantation an average of 9 hours.

Secondary Outcomes (3)

• Occurrence of serious respiratory complication.

  within 48 first hours after liver transplantation.

• Occurrence of thrombotic complication.

  within 48 first hours after liver transplantation.

• Occurrence of serious infectious complication

  within 48 first hours after liver transplantation.

Study Arms (2)

S group

PLACEBO COMPARATOR

S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory

Procedure: Conventional coagulation profile Analysis

R group

EXPERIMENTAL

The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.

Procedure: Rotem analysis

Interventions

Conventional coagulation profile Analysis PROCEDURE

Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter Platelet concentrate : * if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding. * if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if : * if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding. * if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products. Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose. Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF).

S group

Rotem analysis PROCEDURE

Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm Platelet concentrate : * If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm. * If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding. 2 Fresh frozen plasma if CT EXTEM \>100s. Bolus Tranexamic acid 1g and 3g every 24 hours : * if fibrinolysis in EXTEM * Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%. Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure). Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.

R group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients \>=18 years of age
• Patients affiliated to a social security system or similar
• Patients not subject to a measure of legal protection

You may not qualify if:

• Opposition to participation in the study
• Patients \<18 years of age
• Patients who participated in the previous month to another study protocol
• Pregnant women or breast-feeding
• Not affiliated to a social security system
• Patients with hemostasis pathology (hemophilia, ...)

Sponsors & Collaborators

• Laboratoire français de Fractionnement et de Biotechnologies: collaborator
• Hospices Civils de Lyon: lead

Study Sites (1)

Hôpital de la Croix Rousse

Lyon, France

Location

Related Publications (1)

• Bonnet A, Gilquin N, Steer N, Gazon M, Quattrone D, Pradat P, Maynard M, Mabrut JY, Aubrun F. The use of a thromboelastometry-based algorithm reduces the need for blood product transfusion during orthotopic liver transplantation: A randomised controlled study. Eur J Anaesthesiol. 2019 Nov;36(11):825-833. doi: 10.1097/EJA.0000000000001084.

  PMID: 31567574 RESULT

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Aurélie Bonnet, PH

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2014
• First Posted: February 2, 2015
• Study Start: December 1, 2014
• Primary Completion: August 1, 2016
• Study Completion: November 1, 2016
• Last Updated: December 19, 2025

Record last verified: 2025-12

Locations

FR (1)